Biochemistry and Molecular Genetics Department, Hospital Clínic of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain.
German Cancer Research Center, Heidelberg, Germany.
PLoS One. 2019 Jun 24;14(6):e0218716. doi: 10.1371/journal.pone.0218716. eCollection 2019.
The occurrence of endothelial alterations in the liver and in the splanchnic vasculature of cirrhotic patients and experimental models of liver diseases has been demonstrated. However, the pathological role of the portal vein endothelium in this clinical context is scarcely studied and, therefore, deserves attention. In this context, we aimed to investigate whether pathological endothelial activation occurs in the portal vein of cirrhotic rats.
Cirrhosis was induced in wistar rats by CCl4 inhalation. We generated immortalized endothelial cells from the portal vein of control (CT-iPVEC) and cirrhotic rats (CH-iPVEC) by retroviral transduction of the SV40 T antigen. We assessed differential gene expression and intracellular reactive oxygen species (ROS) levels in iPVECs and in portal veins of control and cirrhotic rats. Finally, we assessed the therapeutic effectiveness of cerium oxide nanoparticles (CeO2NP) on reversing PVEC activation and macrophage polarization.
CH-iPVECs overexpressed collagen-I, endothelin-1, TIMP-1, TIMP-2, IL-6 and PlGF genes. These results were consistent with the differential expression showed by whole portal veins from cirrhotic rats. In addition, CH-iPVECs showed a significant increase in intracellular ROS and the capacity of potentiating M1 polarization in macrophages. The treatment of CH-iPVECs with CeO2NPs blocked intracellular ROS formation and IL-6 and TIMP-2 gene overexpression. In agreement with the in vitro results, the chronic treatment of cirrhotic rats with CeO2NPs also resulted in the blockade of both ROS formation and IL-6 gene overexpression in whole portal veins.
Endothelial cells from portal vein of cirrhotic rats depicted an abnormal phenotype characterized by a differential gene expression and the induction of M1 polarization in macrophages. We identified the excess of intracellular reactive oxygen species (ROS) as a major contributor to this altered phenotype. In addition, we demonstrated the utility of the nanomaterial cerium oxide as an effective antioxidant capable of reverse some of these pathological features associated with the portal vein in the cirrhosis condition.
已经证明,肝硬化患者的肝脏和内脏血管内皮发生改变,并且在肝脏疾病的实验模型中也观察到了这种改变。然而,在这种临床情况下,门静脉内皮在其中的病理作用尚未得到充分研究,因此值得关注。在这种情况下,我们旨在研究肝硬化大鼠的门静脉中是否存在病理性内皮激活。
通过 CCl4 吸入诱导 Wistar 大鼠发生肝硬化。我们通过逆转录病毒转导 SV40 T 抗原,从对照组(CT-iPVEC)和肝硬化大鼠(CH-iPVEC)的门静脉中生成永生化内皮细胞。我们评估了 iPVECs 和对照组及肝硬化大鼠门静脉中差异基因表达和细胞内活性氧(ROS)水平。最后,我们评估了氧化铈纳米颗粒(CeO2NP)对逆转 PVEC 激活和巨噬细胞极化的治疗效果。
CH-iPVECs 过度表达胶原-I、内皮素-1、TIMP-1、TIMP-2、IL-6 和 PlGF 基因。这些结果与肝硬化大鼠整个门静脉显示的差异表达一致。此外,CH-iPVECs 显示细胞内 ROS 显著增加,并且增强巨噬细胞 M1 极化的能力增加。用 CeO2NP 处理 CH-iPVECs 可阻断细胞内 ROS 的形成和 IL-6 和 TIMP-2 基因的过度表达。与体外结果一致,慢性给予肝硬化大鼠 CeO2NP 也可阻断整个门静脉中 ROS 形成和 IL-6 基因的过度表达。
肝硬化大鼠门静脉内皮细胞表现出异常表型,其特征为差异基因表达和诱导巨噬细胞 M1 极化。我们确定过多的细胞内活性氧(ROS)是这种改变表型的主要原因。此外,我们证明了纳米材料氧化铈作为一种有效的抗氧化剂的效用,能够逆转与肝硬化门静脉相关的一些病理特征。